Inozyme Pharma, Inc.
INZY · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $20 | $22 | $20 | $22 |
| G&A Expenses | $5 | $5 | $5 | $6 |
| SG&A Expenses | $5 | $5 | $5 | $6 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $0 | $0 | $0 |
| Operating Expenses | $28 | $27 | $25 | $28 |
| Operating Income | -$28 | -$27 | -$25 | -$28 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $0 | $0 | $1 |
| Pre-Tax Income | -$28 | -$27 | -$25 | -$27 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$28 | -$27 | -$25 | -$27 |
| % Margin | – | – | – | – |
| EPS | -0.44 | -0.43 | -0.39 | -0.44 |
| % Growth | -2.3% | -10.3% | 11.4% | – |
| EPS Diluted | -0.44 | -0.43 | -0.39 | -0.44 |
| Weighted Avg Shares Out | 64 | 63 | 63 | 62 |
| Weighted Avg Shares Out Dil | 64 | 63 | 63 | 62 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $2 | $2 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$26 | -$25 | -$23 | -$25 |
| % Margin | – | – | – | – |